Krajina: Južná Afrika
Jazyk: angličtina
Zdroj: South African Health Products Regulatory Authority (SAHPRA)
Ranbaxy
ADCO-AMOCLAV Suspension ADCO-AMOCLAV FORTE Suspension SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): ADCO-AMOCLAV Suspension ADCO-AMOCLAV FORTE Suspension COMPOSITION: Adco-Amoclav Suspension: Each 5 mL of reconstituted suspension contains: Amoxicillin Trihydrate equivalent to amoxicillin 125 mg and Clavulanate potassium equivalent to clavulanic acid 31.25 mg Sodium benzoate 0.2%m/v (as preservative) Butylated hydroxy toluene 0.006% m/v (as antioxidant) Adco-Amoclav Forte Suspension: Each 5 mL of reconstituted suspension contains: Amoxicillin Trihydrate equivalent to amoxicillin 250 mg and Clavulanate potassium equivalent to clavulanic acid 62.5 mg Sodium benzoate 0.2%m/v (as preservative) Butylated hydroxy toluene 0.006% m/v (as antioxidant) PHARMACOLOGICAL CLASSIFICATION: A20.1.2 Penicillins PHARMACOLOGICAL ACTION: Mechanism of action: Adco-Amoclav is a combination of amoxicillin and potassium clavulanate. The amoxicillin component of the formulation exerts a bactericidal action against many strains of Gram positive and Gram-negative organisms. The clavulanic acid component has little or no antimicrobial action. It does, however, by inactivation of susceptible beta- lactamase protect amoxicillin from degradation by beta-lactamase enzymes produced by penicillin resistant strains of organisms. Antibacterial Activity Clavulanic acid is an irreversible inhibitor of beta-lactamases produced by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Proteus vulgaris , H. influenzae, N. gonorrhoeae and B. fragilis( In-vitro activity does not necessarily imply in-vivo efficacy). Potassium clavulanate does not inactivate the chromosomally mediated (Sykes Type 1 Cephalosporinase) beta-lactamases produced by Acinetobacter species, Citrobacter species, Enterobacter, indole positive Prečítajte si celý dokument